Cancer-Attributable Medical Costs for Colorectal Cancer Patients by Phases of Care: What Is the Effect of a Prior Cancer History?

Abstract Medical care costing studies have excluded patients with a prior cancer history. This study aims to update methods for estimating medical care costs attributable to cancer and to evaluate the effect of a prior history of cancer on costs for colorectal cancer (CRC) patients. We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data and matched cancer patients to controls without cancer to estimate cancer-attributable costs by phases of care using Medicare 2007–2013 claims. CRC annualized average cancer-attributable costs were $56.0 K, $5.3 K, $92.5 K, and $24.3 K in the initial, continuing, and end-of-life cancer and noncancer death phases, respectively, in 2014 dollars. Costs were higher for patients diagnosed with more advanced stage, younger ages, and nonwhite races. Costs for patients with prior cancers were consistently higher than patients without prior cancers, especially in the continuing (4.9 K vs 7.2 K) and end-of-life noncancer death (22.7 K vs 30.0 K). Our CRC costs improve previous estimates by using more recent data and updated methods.

Download Full-text

Inequalities in End-Of-Life Care for Colorectal Cancer Patients in Nova Scotia, Canada

Journal of Palliative Care ◽

10.1177/082585971202800205 ◽

2012 ◽

Vol 28 (2) ◽

pp. 90-96 ◽

Cited By ~ 15

Author(s):

André R. Maddison ◽

Yukiko Asada ◽

Fred Burge ◽

Grace W. Johnston ◽

Robin Urquhart

Keyword(s):

Colorectal Cancer ◽

Nova Scotia ◽

End Of Life ◽

Cancer Patients ◽

End Of Life Care ◽

Life Care ◽

Colorectal Cancer Patients

Download Full-text

Complementary medicine use in US adults with a history of colorectal cancer: a nationally representative survey

Supportive Care in Cancer ◽

10.1007/s00520-020-05494-x ◽

2020 ◽

Vol 29 (1) ◽

pp. 271-278

Author(s):

Charlene HL Wong ◽

Tobias Sundberg ◽

Vincent CH Chung ◽

Petra Voiss ◽

Holger Cramer

Keyword(s):

Colorectal Cancer ◽

Cancer Survivors ◽

Cancer Patients ◽

Complementary Medicine ◽

Medicine Use ◽

The Past ◽

The Us ◽

History Of ◽

Mind Body Medicine ◽

Colorectal Cancer Patients

Abstract Background In the USA, colorectal cancer is among the top diagnosed cancers. The current study specifically targets the US adult population that have a history of colorectal cancer. Methods We used the 2017 National Health Interview Survey (NHIS) to investigate the prevalence and predictors of colorectal cancer survivors using complementary medicine in the past 12 months in a representative sample of the US population (N = 26,742). We descriptively analyzed the 12-month prevalence of any complementary medicine use separately for individuals with a prior diagnosis of colorectal cancer and those without. Using chi-squared tests and backward stepwise multiple logistic regression analyses, we identified predictors of complementary medicine use in the past 12 months. Results A weighted total of 1,501,481 US adults (0.6%) had a history of colorectal cancer. More individuals without (weighted n = 76,550,503; 31.2%) than those with a history of colorectal cancer (weighted n = 410,086; 27.3%) had used complementary medicine. The most commonly used complementary medicine among colorectal cancer patients was mind-body medicine, followed by chiropractic. A higher prevalence of complementary medicine use was associated with being female, higher educated and/or living in the US Midwest or South. Conclusions In this study, over one fourth of the US colorectal cancer survivors had used complementary medicine. Mind-body medicine was found to be the most commonly used. With evidence supporting the effectiveness and safety of mind-body medicine use among colorectal cancer patients, promoting the use of evidence-based mind-body medicine for colorectal cancer management could be considered.

Download Full-text

Individual data meta-analysis for the study of survival after pulmonary metastasectomy in colorectal cancer patients: A history of resected liver metastases worsens the prognosis

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2018.03.011 ◽

2018 ◽

Vol 44 (7) ◽

pp. 1006-1012 ◽

Cited By ~ 5

Author(s):

Jon Zabaleta ◽

Tomohiko Iida ◽

Pierre E. Falcoz ◽

Samer Salah ◽

José R. Jarabo ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Cancer Patients ◽

Meta Analysis ◽

Pulmonary Metastasectomy ◽

Individual Data ◽

Resected Liver ◽

History Of ◽

Colorectal Cancer Patients

Download Full-text

Detection of allelic variants of the POLE and POLD1 genes in colorectal cancer patients

Balkan Journal of Medical Genetics ◽

10.1515/bjmg-2017-0028 ◽

2017 ◽

Vol 20 (2) ◽

pp. 83-87 ◽

Cited By ~ 1

Author(s):

LA Pätzold ◽

D Bērziņa ◽

Z Daneberga ◽

J Gardovskis ◽

E Miklaševičs

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

High Performance ◽

Genetic Alterations ◽

Hereditary Colorectal Cancer ◽

Allelic Variants ◽

Cancer History ◽

Unknown Significance ◽

Colorectal Cancer Patients ◽

Cancer Syndromes

Abstract Incidence of colorectal cancer is high worldwide and it mostly occurs as an accumulation of environmental factors and genetic alterations. Hereditary colorectal cancer can develop as a part of a hereditary syndrome. There is a suspected correlation between colorectal cancer and allelic variants of the POLE and POLD1 genes. The aim of the present study was to look for associations between the allelic variants in the POLE and POLD1 genes and colorectal cancer. One thousand, seven hundred and forty-nine DNA samples from colorectal cancer patients were collected from 2002 to 2013. Samples were divided in three groups: hereditary colorectal cancer patients, patients with different hereditary cancer syndromes in their families and patients with no cancer history in their families. The DNA samples were screened for allelic variants of POLE rs483352909 and POLD1 rs39751463 using denaturing high performance liquid chromatography (DHPLC). All patients were negative for allelic variants rs483352909 of the POLE gene and rs397514632 of the POLD1 gene. One allelic variant rs373243003 in the POLE gene and one novel duplication of four nucleotides at the excision site between intron and exon (c.1384-5dupCCTA) in the POLD1 gene, was found. We could not detect or confirm the connection between the genetic variants in the POLD1 and POLE genes and colorectal cancer patients, but we detected a novel genetic variant with an unknown significance.

Download Full-text

Impact of prior cancer history on the survival of patients with larynx cancer

BMC Cancer ◽

10.1186/s12885-020-07634-2 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Kaiquan Zhu ◽

Renyu Lin ◽

Ziheng Zhang ◽

Huanqi Chen ◽

Xingwang Rao

Keyword(s):

Overall Survival ◽

Cancer Patients ◽

Protective Factor ◽

Larynx Cancer ◽

Prior History ◽

Second Primary ◽

Cancer History ◽

History Of ◽

The Impact ◽

History Of Cancer

Abstract Background Patients with a prior history of cancer are commonly excluded from clinical trial. Increasing number of studies implied that a prior cancer did not adversely affect the clinical outcome among various types of cancer patients. However, the impact of prior cancer on survival of larynx cancer patients remains largely unknown. The aim of this study was to evaluate the prevalence of prior cancer and assess its impact on survival of patients diagnosed with larynx cancer. Methods Patients with larynx cancer as the first or second primary malignancy diagnosed from 2004 to 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was conducted to balance baseline characteristics. Kaplan-Meier method, multivariate Cox proportional hazard model, and multivariate competing risk model were performed for survival analysis. Results A total of 24,812 eligible patients with larynx cancer were included in the study, wherein a total of 2436 patients (9.8%) had a prior history of cancer. Prostate (36%), lung and bronchus (10%), urinary bladder (7%), and breast (6%) were the most common types of prior cancer. A prior cancer history served as a risk factor for overall survival (AHR =1.30; 95% CI [1.21–1.41]; P < 0.001) but a protective factor for cancer-specific mortality (AHR = 0.83; 95% CI [0.72–0.94]; P = 0.004) in comparison with those without prior cancer. The subgroup analysis showed that a prior history of cancer adversely affected overall survival of patients with larynx cancer in most subgroups stratified by timing and types of prior cancer, as well as by different clinicopathologic features. Conclusion Our study indicated an adverse survival impact of a prior history of cancer on patients with larynx cancer. Except for a few particular prior cancer, clinical trials should be considered prudently for laryngeal cancer patients with prior cancers.

Download Full-text

Cardiac outcomes of raltitrexed in the treatment of colorectal cancer patients with 5-fluorouracil (5-FU) cardiotoxicity.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e14607 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e14607-e14607

Author(s):

Aryan Firouzbakht ◽

Daniel John Renouf ◽

Leo Chen ◽

Winson Y. Cheung

Keyword(s):

Colorectal Cancer ◽

Myocardial Infarction ◽

Coronary Artery Disease ◽

Coronary Artery ◽

Cancer Patients ◽

Cardiovascular Events ◽

Regression Analyses ◽

History Of ◽

Artery Disease ◽

Colorectal Cancer Patients

e14607 Background: Both 5-FU and raltitrexed are thymidylate synthase inhibitors, but the latter has a toxicity profile that is distinct from 5-FU. Therefore, it is commonly used as an alternative to 5-FU in the treatment of colorectal cancer patients who have a history of cardiac problems or prior 5-FU cardiotoxicity. To date, the population-based risk of cardiac effects from raltitrexed is uncertain. Our aim was to characterize the patterns of treatment and outcomes of patients receiving raltitrexed-based chemotherapy. Methods: We conducted a retrospective study of all patients diagnosed with colorectal cancer from 1988 to 2012, evaluated at 1 of 5 regional cancer centers in British Columbia, Canada and treated with raltitrexed at any point during their disease. At the institutions in our province, raltitrexed use is limited to those in whom 5-FU is contraindicated. Using chi-squared tests and logistic regression analyses, we evaluated the associations between use of raltitrexed and various cardiovascular events, such as angina, myocardial infarction, hypertension and arrhythmias, as well as other toxicity outcomes, including nausea, vomiting and diarrhea. Results: A total of 186 patients were included: median age was 63 years (IQR 55-70), 97 (52%) were men, and 21 (11%) experienced at least one cardiovascular outcome. Only 4 (2%) patients had a documented cardiac history prior to receipt of any systemic therapy. Among the 21 cases of cardiovascular events, 10 reported angina, 1 suffered a myocardial infarction, 6 had hypertension, and 6 experienced arrhythmias. A significant number of patients also presented with other general toxicities: 25 (13%) reported fever, 11 (6%) suffered mucositis, 75 (40%) had nausea, and 51 (27%) experienced diarrhea. On regression analyses, patients with a previous history of coronary artery disease had a higher risk of cardiovascular events than those without (50 vs 11%, p=0.01). Exposure to 5-FU before raltitrexed did not increase cardiovascular outcomes (p=0.81). Conclusions: Raltitrexed is associated with a low risk of cardiovascular events, but its use should be monitored closely in those with prior coronary artery disease.

Download Full-text